An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.

An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.

Item
http://www.wikidata.org/entity/Q37628343
Detection of the onset of ischemia and carcinogenesis by hypoxia-inducible transcription factor-based in vivo bioluminescence imagingToxicologic pathology in the 21st century.Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice.Successful drug development despite adverse preclinical findings part 2: examples.The use of genetically modified mice in cancer risk assessment: challenges and limitations.Opportunities for an alternative integrating testing strategy for carcinogen hazard assessment?Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science.Evaluation of Therapeutics for Advanced-Stage Heart Failure and Other Severely-Debilitating or Life-Threatening Diseases.Regulatory Forum commentary: alternative mouse models for future cancer risk assessment.An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines.Tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in an ultra-short-term skin carcinogenesis bioassay using rasH2 mice.
P2860

An industry perspective on the utility of short-term carcinogenicity testing in transgenic mice in pharmaceutical development.

Item
http://www.wikidata.org/entity/Q37628343
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
An industry perspective on the ...... in pharmaceutical development.
@en
An industry perspective on the ...... in pharmaceutical development.
@nl
type
label
An industry perspective on the ...... in pharmaceutical development.
@en
An industry perspective on the ...... in pharmaceutical development.
@nl
prefLabel
An industry perspective on the ...... in pharmaceutical development.
@en
An industry perspective on the ...... in pharmaceutical development.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P356
P1433
P1476
An industry perspective on the ...... in pharmaceutical development.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698